The results of a model depend, of course, on the assumptions used for
the variables in the model. For example, Dr. Wimo and colleagues
concluded, in another model, that treatment of dementia with an ACEI
was cost neutral. A truly successful disease-modifying treatment
would allow patients to remain at home, avoiding dementia-related long-
term care costs. It is true, though, that any treatment that prolongs
life among the non-productive aged does have a net cost to society.
The issue is, what is the quality of life for those who are treated?
Here the discussion devolves into even more speculation. We don’t
have good measures of life quality among older people with memory
Wimo A, Gaudig M, Schäuble B, Jedenius E. The economic impact of galantamine vs placebo: an analysis based on functional capacity in a Swedish cohort study. J Med Econ. 2012;15(5):1019-24. Abstract
View all comments by James Cooper